drugset / Trial / NCT02120196

Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

NCT02120196

Phase 3 Unknown 100 enrolled Tanta University Tanta University · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

The aim of the study is to compare the effectiveness of rifaximin versus norfloxacin for secondary prevention of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.

Timeline

Start
2014-01
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Norfloxacin Small molecule 400 mg
Subject Rifaximin Other / unclassified 1200 mg